We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Profacgen's PAMPA Services deliver rapid, cost-effective assessment of passive transcellular permeability across diverse biological barriers, supporting early-stage compound screening, oral absorption prediction, and blood-brain barrier penetration evaluation for protein degraders and small molecule drug candidates.
Mechanisms of permeation through biological barriers include active transport, passive diffusion, paracellular transport, and efflux. Passive diffusion is the predominant route of drug absorption, accounting for nearly 80–95% of commercial drugs in the human body. The Parallel Artificial Membrane Permeability Assay (PAMPA) is a passive transcellular permeability model that assesses compounds over a wide pH range and is widely used to predict passive drug transport without the confounding effects of metabolism or active transport.
Figure 1. Schematic illustration of parallel artiicial membranepermeability assay (PAMPA). (Huang et al., 2021)
Overview
PAMPA offers unique advantages for early-stage permeability assessment, particularly when speed, cost, and throughput are critical:
Artificial membrane system: PAMPA employs a lipid-oil-lipid sandwich structure that mimics the lipid bilayer of biological membranes. The artificial membrane separates donor and acceptor compartments, enabling direct measurement of compound flux by passive diffusion alone. This simplified system eliminates cellular variability and transporter interference
Passive permeability measurement: Unlike cell-based assays, PAMPA exclusively measures passive transcellular diffusion, providing unambiguous assessment of intrinsic membrane permeability. This is particularly valuable for distinguishing true permeability liabilities from active transport or efflux effects that complicate cellular assays
High-throughput screening: Pre-coated plate systems enable parallel evaluation of 96 compounds in a single experiment with minimal compound consumption and no cell culture requirements. The 16–24 hour incubation protocol supports rapid turnaround for large library screening
Early-stage compound evaluation: PAMPA's low cost and simplicity make it ideal for initial permeability triage, structure-permeability relationship development, and identification of compounds warranting investment in more complex cell-based or in vivo studies
Our Assay Capabilities
Profacgen provides comprehensive PAMPA services tailored to diverse biological barriers and program requirements:
Passive Permeability Measurement
Quantitative assessment of intrinsic membrane diffusion.
Donor-acceptor flux: Compound placement in donor well with passive diffusion across artificial membrane into acceptor well
Wide pH range: Assessment from pH 4.0 to 8.0 to simulate gastrointestinal tract conditions and understand pH-dependent absorption
LC-MS/MS quantification: Sensitive, specific detection of donor and acceptor concentrations with calibration curve generation
High-Throughput Compound Screening
Rapid evaluation of large compound libraries.
96-well format: Parallel screening of up to 96 compounds per plate with pre-coated artificial membranes
Minimal compound requirement: Low milligram quantities sufficient for full permeability assessment
Quality controls: Caffeine as positive control (high permeability) and famotidine as negative control (low permeability)
Skin-PAMPA: Transdermal penetration evaluation for topical and transdermal drug development
Comparative Permeability Evaluation
Structure-permeability relationship and formulation assessment.
Compound ranking: Relative permeability classification for library triage and analog comparison
pH dependence: Influence of ionization state on permeability to guide formulation pH optimization
Formulation comparison: Oral absorption efficiency assessment for various pharmaceutical preparations
Applications
Our PAMPA platform supports diverse drug discovery and development applications:
Protein degraders: Rapid triage of PROTAC libraries to identify permeability cliffs and guide physicochemical optimization. PAMPA distinguishes true passive permeability limitations from active transport issues, directing medicinal chemistry toward structural modifications that improve membrane crossing
Small molecule screening: Early-stage permeability filtering of large compound collections to prioritize candidates with acceptable absorption potential. Integration with solubility and metabolic stability data enables multi-parameter ADME scoring at the hit-to-lead stage
Lead optimization: Structure-permeability relationship development correlating chemical modifications with PAMPA permeability changes. Identification of optimal lipophilicity, polar surface area, and hydrogen bond donor balance for oral absorption
Early drug discovery: Absorption kinetic parameter determination, biopharmaceutical classification, and formulation strategy guidance before investment in cell-based or in vivo studies. PAMPA data supports go/no-go decisions and resource allocation
Deliverables
Profacgen provides structured documentation aligned with decision-making and regulatory requirements:
Parameter
Description
Permeability Results
Effective permeability (Pe) values, retention factor, and permeability classification (high/moderate/low) with pH-dependent profiles and replicate statistics
Comparative Analysis
Compound ranking, structure-permeability correlations, and formulation comparison with reference compound benchmarking
Experimental Report
Detailed methodology, membrane composition, buffer conditions, LC-MS/MS validation, quality control data, and regulatory-compliant summary
Easier, Faster, and Less Expensive: No cell culture, no transporter interference, and minimal compound requirements make PAMPA the most cost-effective permeability screen for early-stage programs.
Wide pH Range Assessment: Evaluation across pH 4.0–8.0 simulates conditions from stomach to intestine, enabling comprehensive understanding of pH-dependent absorption and formulation optimization.
Barrier-Specific Models: PAMPA-GIT, PAMPA-BBB, and Skin-PAMPA variants predict permeability across intestinal, blood-brain, and dermal barriers with tailored lipid compositions.
High-Throughput Compatibility: 96-well pre-coated plates enable parallel screening of large libraries, supporting rapid structure-permeability relationship development and lead optimization cycles.
Representative Program Scenarios
Scenario 1: PAMPA-GIT Screening for PROTAC Library Triage
Program Context:
A PROTAC program generated 80 analogs requiring rapid permeability assessment to identify cellular uptake liabilities before investment in expensive cell-based degradation assays.
Objective:
To rank all 80 analogs by PAMPA-GIT permeability within 2 weeks, identify structure-permeability relationships, and prioritize candidates for cellular validation.
Approach:
Profacgen performed PAMPA-GIT in 96-well format at pH 6.5 and 7.4 with lecithin-based artificial membranes. Compounds were screened at 25 µM with 16-hour incubation. Donor and acceptor concentrations were quantified by LC-MS/MS. Effective permeability (Pe) was calculated and correlated with molecular weight, polar surface area, and calculated lipophilicity.
Outcome:
PAMPA screening identified a clear permeability cliff at polar surface area >160 Ų. Fifteen analogs achieved high permeability (Pe > 2.0 × 10−6 cm/s), 35 showed moderate permeability, and 30 were classified as low permeability. The high-permeability group demonstrated significantly better cellular degradation (p < 0.01), validating PAMPA as a predictive filter. Structure-permeability insights guided focused synthesis of 10 new analogs with improved passive diffusion.
Scenario 2: PAMPA-BBB for CNS-Targeted Degrader Optimization
Program Context:
A neurodegeneration program required a brain-penetrant degrader with confirmed blood-brain barrier permeability. Cell-based assays suggested moderate permeability but could not distinguish passive diffusion from efflux effects.
Objective:
To employ PAMPA-BBB to assess intrinsic passive brain penetration potential and identify whether poor CNS exposure resulted from passive permeability or P-gp-mediated efflux.
Approach:
Profacgen performed PAMPA-BBB with a specialized lipid formulation mimicking brain microvascular endothelial membranes. The degrader and reference compounds (caffeine, famotidine) were evaluated at pH 7.4. Parallel MDCK-MDR1 studies assessed P-gp efflux contribution. The degrader was compared to analogs with reduced hydrogen bond donors and increased lipophilicity.
Outcome:
PAMPA-BBB revealed moderate passive permeability (Pe = 1.2 × 10−6 cm/s), suggesting intrinsic BBB crossing capability. MDCK-MDR1 identified strong P-gp efflux (efflux ratio = 8.5) as the limiting factor. Analogs with fewer H-bond donors maintained PAMPA-BBB permeability while reducing MDCK efflux ratio to 2.1. The optimized lead achieved brain-to-plasma ratio of 0.4 in vivo, confirming that PAMPA-BBB plus efflux assessment accurately predicted CNS penetration.
Q: What is the difference between PAMPA and cell-based permeability assays?
A: PAMPA measures only passive transcellular diffusion across artificial lipid membranes without cells, transporters, or metabolism. Caco-2 and MDCK are cell-based models that capture active transport, efflux, and paracellular pathways. PAMPA is faster and cheaper but cannot assess transporter-mediated effects. We recommend PAMPA for initial screening and cell-based assays for mechanistic follow-up.
Q: Can PAMPA predict oral bioavailability?
A: PAMPA predicts intestinal absorption fraction, which is one component of oral bioavailability. Complete bioavailability also depends on solubility, first-pass metabolism, and formulation. We integrate PAMGA permeability with solubility and metabolic stability data for more comprehensive bioavailability prediction.
Q: Which PAMPA variant should I choose?
A: PAMPA-GIT predicts gastrointestinal absorption for oral drugs. PAMPA-BBB assesses blood-brain barrier penetration for CNS-targeted compounds. Skin-PAMPA evaluates transdermal penetration for topical formulations. We guide selection based on your target tissue and therapeutic indication.
Q: Why does PAMPA use a 16–24 hour incubation?
A: The extended incubation allows sufficient compound flux across the artificial membrane for reliable quantification, particularly for low-permeability compounds. Unlike cell-based assays with active transport, PAMPA relies solely on passive diffusion, which is slower. The incubation time is optimized for sensitivity while maintaining membrane stability.
Q: How much compound is required for PAMPA?
A: PAMPA requires minimal compound—typically 1–2 mg at >95% purity for a full pH-dependent study. High-throughput screening of 50–100 compounds requires proportionally more material. DMSO stock solutions (10 mM) are preferred. The low compound consumption is a major advantage over cell-based assays.
Q: What is the typical turnaround for PAMPA studies?
A: Single compound PAMPA-GIT with pH profiling requires 5–7 days. High-throughput screening of 50–100 compounds in 96-well format requires 1–2 weeks. PAMPA-BBB and Skin-PAMPA require similar timelines. Rush services are available for urgent programs.
References:
Huang Y, Chen Y, Lu S, Zhao C. Recent advance of in vitro models in natural phytochemicals absorption and metabolism. eFood. 2021;2(6):307-318. doi:10.53365/efood.k/146945
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
Figure 1. Schematic illustration of parallel artiicial membranepermeability assay (PAMPA). (Huang et al., 2021)